Advanced search
Publication Cover
Current Medical Research and Opinion Volume 21, 2005 - Issue 12
Submit an article Journal homepage
164
Views
24
CrossRef citations to date
0
Altmetric
Brief Report

The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial

Yongming Qu Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
,
Mayme Wong Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]
,
Daniel Thiebaud Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
&
John L. Stock Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
Pages 1955-1959 | Accepted 06 Oct 2005, Published online: 28 Oct 2005

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Aska Toda, Kenjiro Sawada, Akihiko Yoshimura, Erika Nakatsuka, Hiromasa Kuroda, Katsumi Kozasa, Mayuko Miyamoto, Kae Hashimoto, Seiji Mabuchi & Tadashi Kimura. (2017) Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifene. International Journal of Women's Health 9, pages 821-825.
Read now
Saeko Fujiwara, Etsuro Hamaya, Masayo Sato, Peita Graham-Clarke, Jennifer A Flynn & Russel Burge. (2014) Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia). Clinical Interventions in Aging 9, pages 1879-1893.
Read now
Seung Sang Ko & V Craig Jordan. (2011) Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert Opinion on Pharmacotherapy 12:4, pages 657-674.
Read now
Enrico M Messalli & Cono Scaffa. (2009) Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update. International Journal of Women's Health 1, pages 11-20.
Read now
S. Scharla, H. Oertel, K. Helsberg, F. Kessler, F. Langer & T. Nickelsen. (2006) Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration. Current Medical Research and Opinion 22:12, pages 2393-2402.
Read now

Articles from other publishers (19)

Mina Nicole Händel, Isabel Cardoso, Cecilie von Bülow, Jeanett Friis Rohde, Anja Ussing, Sabrina Mai Nielsen, Robin Christensen, Jean-Jacques Body, Maria Luisa Brandi, Adolfo Diez-Perez, Peyman Hadji, Muhammad Kassim Javaid, Willem Frederik Lems, Xavier Nogues, Christian Roux, Salvatore Minisola, Andreas Kurth, Thierry Thomas, Daniel Prieto-Alhambra, Serge Livio Ferrari, Bente Langdahl & Bo Abrahamsen. (2023) Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ, pages e068033.
Crossref
Yasser El Miedany. 2022. New Horizons in Osteoporosis Management. New Horizons in Osteoporosis Management 277 295 .
J. M. D. A. Rollo, R. S. Boffa, R. Cesar, R. Erbereli, D. C. Schwab & T. P. Leivas. 2020. The Computational Mechanics of Bone Tissue. The Computational Mechanics of Bone Tissue 45 68 .
Emily E. Carmody. 2017. Fragility Fractures of the Pelvis. Fragility Fractures of the Pelvis 251 259 .
Esther M. M. van de Glind, Hanna C. Willems, Saeid Eslami, Ameen Abu-Hanna, Willem F. Lems, Lotty Hooft, Sophia E. de Rooij, Dennis M. Black & Barbara C. van Munster. (2016) Estimating the Time to Benefit for Preventive Drugs with the Statistical Process Control Method: An Example with Alendronate. Drugs & Aging 33:5, pages 347-353.
Crossref
Petra Stute & Martin Birkhäuser. (2015) Selektive Östrogenrezeptormodulatoren (SERM)Selective estrogen receptor modulators (SERM). Gynäkologische Endokrinologie 13:2, pages 126-134.
Crossref
J.M.D.A. Rollo, R.S. Boffa, R. Cesar, D.C. Schwab & T.P. Leivas. (2015) Assessment of Trabecular Bones Microarchitectures and Crystal Structure of Hydroxyapatite in Bone Osteoporosis with Application of the Rietveld Method. Procedia Engineering 110, pages 8-14.
Crossref
Wen-Ling Lee, Ming-Huei Cheng, Der-Cherng Tarng, Wu-Chang Yang, Fa-Kung Lee & Peng-Hui Wang. (2013) The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease—chronic kidney disease—mineral and bone disorder: Osteoporosis. Journal of the Chinese Medical Association 76:7, pages 365-371.
Crossref
Angelo A. Licata. (2013) Bone density, bone quality, and FRAX: changing concepts in osteoporosis management. American Journal of Obstetrics and Gynecology 208:2, pages 92-96.
Crossref
Noriko Iikuni, Etsuro Hamaya, Shigeru Nihojima, Shunji Yokoyama, Wakana Goto, Masanori Taketsuna, Akimitsu Miyauchi & Hideaki Sowa. (2012) Safety and effectiveness profile of raloxifene in long-term, prospective, postmarketing surveillance. Journal of Bone and Mineral Metabolism 30:6, pages 674-682.
Crossref
Charles A. Inderjeeth, Kien Chan, Kevin Kwan & Michelle Lai. (2012) Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments. Journal of Bone and Mineral Metabolism 30:5, pages 493-503.
Crossref
Mark Brincat, Jean Calleja-Agius, C. Tamer Erel, Marco Gambacciani, Irene Lambrinoudaki, Mette H. Moen, Karin Schenck-Gustafsson, Florence Tremollieres, Svetlana Vujovic, Margaret Rees & Serge Rozenberg. (2011) EMAS position statement: Bone densitometry screening for osteoporosis. Maturitas 68:1, pages 98-101.
Crossref
Steven R. Goldstein, Claire S. Duvernoy, Joaquim Calaf, Jonathan D. Adachi, John L. Mershon, Sherie A. Dowsett, Donato Agnusdei & Cynthia A. Stuenkel. (2009) Raloxifene use in clinical practice. Menopause 16:2, pages 413-421.
Crossref
Rujuta H. Patel & Kenneth W. Lyles. 2009. Osteoporosis in Older Persons. Osteoporosis in Older Persons 71 81 .
Wen-Ling Lee, Hsiang-Tai Chao, Ming-Huei Cheng & Peng-Hui Wang. (2008) Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Maturitas 60:2, pages 92-107.
Crossref
Wendy Shelly, Michael W. Draper, Venkatesh Krishnan, Mayme Wong & Robert B. Jaffe. (2008) Selective Estrogen Receptor Modulators: An Update on Recent Clinical Findings. Obstetrical & Gynecological Survey 63:3, pages 163-181.
Crossref
FELICIA COSMAN & ROBERT LINDSAY. 2007. Treatment of the Postmenopausal Woman. Treatment of the Postmenopausal Woman 837 845 .
Christian Alexandre. (2006) Les SERM(s). Revue du Rhumatisme 73:8, pages 828-833.
Crossref
Toshitaka Nakamura, Jian Li Liu, Hirotoshi Morii, Qi Ren Huang, Han Min Zhu, Yongming Qu, Etsuro Hamaya & Daniel Thiebaud. (2006) Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis. Journal of Bone and Mineral Metabolism 24:5, pages 414-418.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.